Intranasal insulin could benefit patients with Alzheimer's, MCI

07/20/2010 | Medscape (free registration)

A trial involving patients with mild cognitive impairment and Alzheimer's disease showed that administering intranasal insulin for four months improved memory and cognitive function, as well as cerebrospinal fluid biomarker profiles, among the patients. FDG-PET imaging also showed that glucose metabolism was intact in areas affected by Alzheimer's pathology in those who received insulin.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC